Provision Proton Therapy
A board-certified radiation oncologist, Dr. Fagundes is the medical director of the Provision Center for Proton Therapy and a physician with Provision Medical Group in Knoxville, Tennessee. Previously with ProCure Proton Therapy Center in Oklahoma City, Dr. Fagundes first became interested in proton therapy during his internship and residency at the University of Miami Jackson Memorial Hospital, where he had the opportunity to guest intern at Harvard University. Upon his completion of his residency, Dr. Fagundes went back to Harvard Medical School for his fellowship, where he began treating patients with proton therapy.
During his fellowship he published a paper in collaboration with his senior staff at the Harvard Cyclotron Proton Center, Dr. Eugene Hug, on the treatment of base of skull chordomas. This paper was presented at ASTRO (American Society of Radiation Oncologists) annual conference and was published in The International Journal of Radiation Oncology. Dr. Fagundes was an assistant professor at TUFTS University in Boston, where he developed protocols for treatment and retreatment using a new modality, IMRT, which at the time was not yet FDA approved. He is now the principal investigator in Oklahoma for the University of Pennsylvania’s retreatment protocol using proton therapy. He earned his medical degree at Universidade Federal do RGS in Porto Alegre, Brazil, where he is originally from.
Between 2011- 2013, Dr. Fagundes developed a “Phase II Study of Post-operative, Cardiac Sparing Proton Radiotherapy for women with Stage III, Loco-Regional, Non-metastatic Breast Cancer”, in collaboration with Dr. Eugen Hug at ProCure. The dosimetric results showing the advantages of Proton therapy in cardiac and coronary artery sparing were accepted to the PTCOG (Proton Therapy Co-Operative Group) and ASTRO meetings, 2013.